McKESSON’s DoD PRIME VENDOR CONTRACT VALUED AT $100 MIL. OVER FIVE YEARS
McKESSON's DoD PRIME VENDOR CONTRACT VALUED AT $100 MIL. OVER FIVE YEARS and designates McKesson as the sole distributor of pharmaceuticals for 11 military hospitals in the National Capital (Washington, D.C.) region. Announced by the Department of Defense Feb. 10, the contract is the first in the department's pilot project to use one prime vendor for pharmaceuticals and one for medical/surgical supplies in each of DoD's 22 regions of the U.S. ("The Pink Sheet" Aug. 17, 1992, T&G-2). The med/surg distributor for the National Capital region is expected to be named by early March. DoD is expected to make its next awards for the Philadelphia- area region, followed by the San Francisco and San Diego regions in late April and the Tidewater/North Carolina region sometime later. D.C., San Francisco, San Diego and Tidewater together account for about $90 mil. in annual DoD drug purchases. DoD went forward with the McKesson award despite a pending protest filed by Renow, a Norfolk, Va.-based wholesaler. The General Accounting Office is reviewing Renow's contention that DoD's selection process favors large wholesalers ("The Pink Sheet" Dec. 7, 1992, In Brief). DoD's contract procedures allow top officials to permit a contract to be awarded in the face of a protest if the matter is considered to have some urgency. DoD also indicated that it believes it has made a strong case to GAO. San Francisco-based McKesson has operations in all 50 states and is bidding on additional DoD regions for both drug and med/surg prime vendor contracts. McKesson also is the prime vendor for the Veterans Affairs Department's Northwest region, a contract valued at $12 mil. annually. The DoD program will allow military hospitals to consolidate pharmaceutical purchases and deliveries and will move to totally electronic ordering and payment procedures within about two years. The department will maintain a central "computer catalog" of products and alert hospitals to interim discounts and special offers from manufacturers.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth